Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

Viking Therapeutic (VKTX) Positive Early Data in X-ALD Adds New Future Catalyst - Raymond James

Raymond James analyst Steve Seedhouse reiterated an Outperform rating and $12.00 price target on Viking Therapeutic (NASDAQ: VKTX) after the company reported topline data from a Phase 1 study evaluating oral thyroid hormone receptor beta (THR-) agonist, VK0214.

VK0214 treatment resulted in statistically significant reductions in LDL... More